艾蘆庫單抗

化合物

艾蘆庫單抗INN:Icrucumab;開發代號:IMC-18F1)是一種人單株抗體,設計用於治療實體瘤[1][2]艾蘆庫單抗由ImClone Systems英語ImClone Systems公司開發,正在進行I期試驗。[3]

艾蘆庫單抗
單株抗體
種類完整抗體
目標VEGFR英語VEGF receptor-1
臨床資料
其他名稱IMC-18F1
ATC碼
  • 未分配
識別資訊
CAS號1024603-92-6  ☒N
ChemSpider
  • none
UNII
KEGG
化學資訊
化學式C6514H10024N1756O2032S42
摩爾質量146,796.63 g·mol−1

參考資料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab (PDF). American Medical Association. [2024-01-21]. (原始內容存檔 (PDF)於2012-09-28). 
  2. ^ LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. April 2014, 32 (2): 303–11. PMID 23903897. S2CID 34756277. doi:10.1007/s10637-013-9998-8. 
  3. ^ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov